AstraZeneca plc Company Profile (LON:AZN)

About AstraZeneca plc (LON:AZN)

AstraZeneca plc logoAstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience. In CVMD, it is expanding its portfolio into the cardiovascular-renal area with late-stage assets, such as ZS-9 and roxadustat, as well as investing to explore the benefits of its SGLT2 and GLP-1 franchises in chronic kidney disease (CKD) and heart failure (HF). The Company has approximately 40 projects in Phase I, including 29 new molecular entities (NMEs), and 11 oncology combination projects. It has approximately 40 projects in Phase II, including 25 NMEs; four significant additional indications for projects that have reached phase II, and seven oncology combination projects.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Pharmaceuticals - NEC
  • Sub-Industry: N/A
  • Symbol: LON:AZN
  • CUSIP: N/A
  • Web: www.astrazeneca.com/
Capitalization:
  • Market Cap: £65.22 billion
  • Outstanding Shares: 1,266,000,000
Average Prices:
  • 50 Day Moving Avg: GBX 5,235.89
  • 200 Day Moving Avg: GBX 4,847.81
  • 52 Week Range: GBX 3,996 - GBX 5,520
P/E:
  • Trailing P/E Ratio: 19.30
  • P/E Growth: 3.24
Sales & Book Value:
  • Annual Revenue: £22.29 billion
  • Price / Sales: 2.93
  • Book Value: GBX 10.26 per share
  • Price / Book: 5.02
Dividend:
  • Dividend Yield: 4.2%
Profitability:
  • EBIDTA: £5.84 billion
  • Net Margins: 9.47%
  • Return on Equity: 15.47%
  • Return on Assets: 3.33%
Misc:
  • Average Volume: 1.97 million shs.
 
Frequently Asked Questions for AstraZeneca plc (LON:AZN)

What is AstraZeneca plc's stock symbol?

AstraZeneca plc trades on the London Stock Exchange (LON) under the ticker symbol "AZN."

How often does AstraZeneca plc pay dividends? What is the dividend yield for AstraZeneca plc?

AstraZeneca plc declared a dividend on Thursday, February 2nd. Shareholders of record on Thursday, February 16th will be paid a dividend of GBX 150.20 per share on Monday, March 20th. This represents a yield of 3.52%. The ex-dividend date of this dividend is Thursday, February 16th. This is a positive change from AstraZeneca plc's previous dividend of $68.70. The official announcement can be accessed at this link. View AstraZeneca plc's Dividend History.

When will AstraZeneca plc make its next earnings announcement?

AstraZeneca plc is scheduled to release their next quarterly earnings announcement on Wednesday, July, 26th 2017. View Earnings Estimates for AstraZeneca plc.

Where is AstraZeneca plc's stock going? Where will AstraZeneca plc's stock price be in 2017?

20 brokers have issued twelve-month price targets for AstraZeneca plc's shares. Their predictions range from GBX 3,900 to GBX 6,500. On average, they expect AstraZeneca plc's stock price to reach GBX 5,257.16 in the next twelve months. View Analyst Ratings for AstraZeneca plc.

Who are some of AstraZeneca plc's key competitors?

Who are AstraZeneca plc's key executives?

AstraZeneca plc's management team includes the folowing people:

  • Pascal Soriot, Executive Director and Chief Executive Officer
  • Marc Dunoyer, Executive Director, Chief Financial Officer
  • Fiona Cicconi, Executive Vice-President, Human Resources
  • Sean Bohen M.D., Ph.D., Chief Medical Officer, Executive Vice President - Global Medicines Development
  • Pam P. Cheng, Executive Vice President - Operations and Information Technology
  • Ruud Dobber, Executive Vice President, North America
  • Bahija Jallal Ph.D., Executive Vice President, MedImmune
  • Mark Mallon, Executive Vice President, Global Product and Portfolio Strategy, Global Medical Affairs & Corporate Affairs Executive Vice-President, International West
  • Menelas Pangalos, Executive Vice President - IMED Biotech Unit and Global Business Development
  • Leon Wang, Executive Vice President - Asia Pacific

How do I buy AstraZeneca plc stock?

Shares of AstraZeneca plc and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is AstraZeneca plc's stock price today?

One share of AstraZeneca plc stock can currently be purchased for approximately GBX 5,152.


MarketBeat Community Rating for AstraZeneca plc (LON AZN)
Community Ranking:  2.1 out of 5 ( )
Outperform Votes:  815 (Vote Outperform)
Underperform Votes:  1,157 (Vote Underperform)
Total Votes:  1,972
MarketBeat's community ratings are surveys of what our community members think about AstraZeneca plc and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for AstraZeneca plc (LON:AZN) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 3 Sell Ratings, 8 Hold Ratings, 9 Buy Ratings
Consensus Rating:Hold (Score: 2.30)
Consensus Price Target: GBX 5,257.16

Analysts' Ratings History for AstraZeneca plc (LON:AZN)
Show:
DateFirmActionRatingPrice TargetDetails
7/21/2017J P Morgan Chase & CoReiterated RatingNeutralView Rating Details
7/21/2017BNP ParibasReiterated RatingNeutralView Rating Details
7/14/2017Goldman Sachs Group, Inc. (The)Reiterated RatingSellGBX 3,900View Rating Details
7/13/2017Shore CapitalReiterated RatingHoldView Rating Details
7/13/2017Kepler Capital MarketsReiterated RatingBuyGBX 5,500View Rating Details
7/13/2017Liberum CapitalReiterated RatingBuyGBX 5,500View Rating Details
7/13/2017Citigroup Inc.Reiterated RatingBuyGBX 6,000View Rating Details
7/12/2017Jefferies Group LLCLower Price TargetHoldGBX 5,500 -> GBX 5,300View Rating Details
7/4/2017HSBC Holdings plcDowngradeReduceGBX 4,500View Rating Details
7/3/2017Barclays PLCBoost Price TargetOverweightGBX 6,000 -> GBX 6,300View Rating Details
6/30/2017Deutsche Bank AGReiterated RatingBuyGBX 5,700View Rating Details
6/23/2017Morgan StanleyReiterated RatingOverweightGBX 5,600View Rating Details
6/19/2017Credit Suisse GroupReiterated RatingNeutralGBX 5,000View Rating Details
5/26/2017InvestecBoost Price TargetHoldGBX 4,600 -> GBX 5,000View Rating Details
5/17/2017Berenberg BankBoost Price TargetBuyGBX 5,670 -> GBX 5,850View Rating Details
4/28/2017Sanford C. BernsteinSet Price TargetNeutralGBX 4,736View Rating Details
4/27/2017S&P GlobalSet Price TargetSellGBX 4,500View Rating Details
4/3/2017Beaufort SecuritiesReiterated RatingHoldView Rating Details
3/23/2017Societe GeneraleReiterated RatingBuyView Rating Details
2/28/2017Bryan, Garnier & CoReiterated RatingBuyGBX 5,400View Rating Details
6/24/2016Independent Research GmbHSet Price TargetSellGBX 3,650View Rating Details
5/10/2016Oddo SecuritiesReiterated RatingBuyGBX 5,400View Rating Details
5/5/2016Charles StanleyUpgradeStrong-BuyView Rating Details
3/24/2016NatixisReiterated RatingNeutralGBX 4,456View Rating Details
3/23/2016NomuraLower Price TargetHoldGBX 4,880 -> GBX 4,350View Rating Details
2/12/2016Baader BankReiterated RatingHoldGBX 4,400View Rating Details
2/9/2016AlphaValueUpgradeBuyGBX 4,640View Rating Details
2/4/2016S&P Equity ResearchSet Price TargetNeutralGBX 4,500View Rating Details
2/2/2016HandelsbankenReiterated RatingAccumulateGBX 5,220.30View Rating Details
1/28/2016Pareto SecuritiesReiterated RatingSellGBX 3,855.35View Rating Details
1/27/2016SwedbankReiterated RatingBuyGBX 5,115.47View Rating Details
1/13/2016Nordea Equity ResearchReiterated RatingHoldGBX 4,698.35View Rating Details
(Data available from 7/23/2015 forward)

Earnings

Earnings History for AstraZeneca plc (LON:AZN)
Earnings by Quarter for AstraZeneca plc (LON:AZN)
Earnings History by Quarter for AstraZeneca plc (LON AZN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/26/2017$0.85N/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for AstraZeneca plc (LON:AZN)
Current Year EPS Consensus Estimate: $3.72 EPS

Dividends

Dividend History by Quarter for AstraZeneca plc (LON AZN)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
2/2/2017GBX 150.203.52%2/16/20172/16/20173/20/2017
7/28/2016GBX 68.701.37%8/11/20168/11/20169/12/2016
2/4/2016GBX 1313.16%2/18/20162/18/20163/21/2016
7/30/2015GBX 57.501.33%8/13/20158/13/20159/14/2015
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for AstraZeneca plc (LON:AZN)
Insider Trades by Quarter for AstraZeneca plc (LON:AZN)
Insider Trades by Quarter for AstraZeneca plc (LON:AZN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/27/2015Courtois,Jean-PhilippeInsiderBuy900GBX 4,423£39,807
8/28/2015Soriot,PascalInsiderBuy76,300GBX 3,960£3,021,480
5/7/2015Marc DunoyerInsiderBuy10,000GBX 4,397£439,700
4/30/2015Ann CairnsInsiderBuy1,100GBX 4,455£49,005
4/29/2015Shriti VaderaInsiderBuy3,500GBX 4,563£159,705
4/28/2015Graham ChipchaseInsiderBuy1,100GBX 4,606£50,666
4/27/2015Bruce BurlingtonInsiderBuy600GBX 4,662£27,972
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for AstraZeneca plc (LON:AZN)
Latest Headlines for AstraZeneca plc (LON:AZN)
Source:
DateHeadline
americanbankingnews.com logoAstraZeneca plc (AZN) Rating Reiterated by J P Morgan Chase & Co
www.americanbankingnews.com - July 22 at 12:18 PM
americanbankingnews.com logoAstraZeneca plc (LON:AZN) Receives "Neutral" Rating from BNP Paribas
www.americanbankingnews.com - July 21 at 8:16 AM
americanbankingnews.com logoAstraZeneca plc (AZN) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - July 21 at 7:36 AM
seekingalpha.com logoChaos At AstraZeneca - Seeking Alpha
seekingalpha.com - July 19 at 10:33 PM
americanbankingnews.com logoAstraZeneca plc (LON:AZN) to Release Earnings on Wednesday
www.americanbankingnews.com - July 19 at 2:58 AM
nasdaq.com logoAstraZeneca (AZN) CEO Rumor Reportedly Ends, Shares Rise - Nasdaq
www.nasdaq.com - July 17 at 9:39 PM
finance.yahoo.com logoAstraZeneca (AZN) CEO Rumor Reportedly Ends, Shares Rise
finance.yahoo.com - July 17 at 9:38 PM
finance.yahoo.com logoCEO departures not always bad for companies: Cramer
finance.yahoo.com - July 17 at 9:38 PM
thestreet.com logoAstraZeneca Shares Slump On Reports Teva Courting CEO Pascal Soriot - TheStreet.com
www.thestreet.com - July 14 at 11:13 PM
thestreet.com logoPotential AstraZeneca C-Suite Shuffle Rekindles Takeover Chatter - TheStreet.com
www.thestreet.com - July 14 at 6:11 PM
americanbankingnews.com logoGoldman Sachs Group, Inc. (The) Reiterates GBX 3,900 Price Target for AstraZeneca plc (AZN)
www.americanbankingnews.com - July 14 at 11:37 AM
nasdaq.com logoBUZZ-US STOCKS ON THE MOVE-Yandex, AstraZeneca, Target, Teva, Delta Air Lines - Nasdaq
www.nasdaq.com - July 13 at 10:18 PM
finance.yahoo.com logo[$$] Mystery at AstraZeneca: Is CEO Pascal Soriot Staying or Going?
finance.yahoo.com - July 13 at 10:18 PM
feeds.benzinga.com logoAnalyst Wonders If AstraZeneca's CEO Would Be A Fit At Teva
feeds.benzinga.com - July 13 at 5:28 PM
wsj.com logoMystery at AstraZeneca: Is CEO Pascal Soriot Staying or Going?
www.wsj.com - July 13 at 5:13 PM
nasdaq.com logoAstraZeneca is Oversold - Nasdaq
www.nasdaq.com - July 13 at 5:13 PM
seekingalpha.com logoIs Parting Such Sweet Soriot For AstraZeneca? - Seeking Alpha
seekingalpha.com - July 13 at 5:13 PM
americanbankingnews.com logoAstraZeneca plc (AZN) Earns "Hold" Rating from Shore Capital
www.americanbankingnews.com - July 13 at 3:06 PM
americanbankingnews.com logoAstraZeneca plc's (LON:AZN) Neutral Rating Reaffirmed at J P Morgan Chase & Co
www.americanbankingnews.com - July 13 at 6:58 AM
marketwatch.com logoLondon Markets: FTSE 100 slips as AstraZeneca slides
www.marketwatch.com - July 13 at 5:16 AM
finance.yahoo.com logoPerformance of AstraZeneca Stock in 2Q17
finance.yahoo.com - July 10 at 4:22 PM
americanbankingnews.com logoAstraZeneca plc (LON:AZN) Stock Rating Reaffirmed by Citigroup Inc.
www.americanbankingnews.com - July 9 at 9:40 PM
americanbankingnews.com logoBarclays PLC Boosts AstraZeneca plc (AZN) Price Target to GBX 6,300
www.americanbankingnews.com - July 3 at 1:33 PM
americanbankingnews.com logoAstraZeneca plc (AZN) Receives "Buy" Rating from Deutsche Bank AG
www.americanbankingnews.com - July 1 at 10:34 PM
finance.yahoo.com logoAnalyst Recommendations for AstraZeneca in June 2017
finance.yahoo.com - June 30 at 9:27 PM
nasdaq.com logoCanada's top court hands patent win to pharmaceutical companies - Nasdaq
www.nasdaq.com - June 30 at 4:22 PM
americanbankingnews.com logoAstraZeneca plc (AZN) Given Consensus Recommendation of "Hold" by Analysts
www.americanbankingnews.com - June 26 at 7:44 AM
americanbankingnews.com logoAstraZeneca plc (AZN) Rating Reiterated by Morgan Stanley
www.americanbankingnews.com - June 23 at 7:14 AM
finance.yahoo.com logo[$$] Repare Therapeutics Grabs $68 Million, Targets 'Synthetic Lethality' in Cancer
finance.yahoo.com - June 22 at 8:56 PM
americanbankingnews.com logoAstraZeneca plc (AZN) Receives Neutral Rating from Credit Suisse Group
www.americanbankingnews.com - June 19 at 11:52 PM
americanbankingnews.com logoAstraZeneca plc (AZN) Given Hold Rating at Shore Capital
www.americanbankingnews.com - June 17 at 10:58 PM
americanbankingnews.com logoJefferies Group LLC Boosts AstraZeneca plc (AZN) Price Target to GBX 5,500
www.americanbankingnews.com - June 17 at 1:38 PM
americanbankingnews.com logoAstraZeneca plc (AZN) Given Buy Rating at Deutsche Bank AG
www.americanbankingnews.com - June 17 at 1:02 PM
rttnews.com logoAstraZeneca Presents New Data On Farxiga
www.rttnews.com - June 12 at 4:48 PM
nasdaq.com logoDecember 15th Options Now Available For AstraZeneca (AZN)
www.nasdaq.com - June 12 at 4:48 PM
finance.yahoo.com logoWhen to Roll Over
finance.yahoo.com - June 12 at 4:48 PM
americanbankingnews.com logoMorgan Stanley Reiterates "Buy" Rating for AstraZeneca plc (AZN)
www.americanbankingnews.com - June 11 at 2:02 PM
americanbankingnews.com logoAstraZeneca plc (AZN) Receives Hold Rating from Shore Capital
www.americanbankingnews.com - June 8 at 11:02 PM
nasdaq.com logoAstraZeneca (AZN) Divests Migraine Drug Rights Beyond Japan - Nasdaq
www.nasdaq.com - June 8 at 9:32 PM
marketwatch.com logoAstraZeneca to sell Zomig migraine drug rights - MarketWatch
www.marketwatch.com - June 7 at 8:04 AM
finance.yahoo.com logoAstraZeneca sells migraine drug for up to $302 mln
finance.yahoo.com - June 7 at 8:04 AM
americanbankingnews.com logoAstraZeneca plc (AZN) Given a GBX 4,500 Price Target at HSBC Holdings plc
www.americanbankingnews.com - June 6 at 7:28 AM
americanbankingnews.com logoAstraZeneca plc's (AZN) "Overweight" Rating Reiterated at Barclays PLC
www.americanbankingnews.com - June 5 at 3:40 PM
marketwatch.com logoAstraZeneca: Lynparza trial meets primary endpoint - MarketWatch
www.marketwatch.com - June 5 at 3:16 PM
finance.yahoo.com logoTesaro Crashes Despite Beating AstraZeneca With 'Stronger' Data
finance.yahoo.com - June 5 at 3:16 PM
americanbankingnews.com logoAstraZeneca plc (AZN) Stock Rating Reaffirmed by Kepler Capital Markets
www.americanbankingnews.com - June 5 at 1:08 PM
americanbankingnews.com logoAstraZeneca plc (AZN) Given Neutral Rating at JPMorgan Chase & Co.
www.americanbankingnews.com - June 5 at 11:44 AM
americanbankingnews.com logoDeutsche Bank AG Reaffirms "Buy" Rating for AstraZeneca plc (AZN)
www.americanbankingnews.com - June 5 at 6:42 AM
americanbankingnews.com logoLiberum Capital Reiterates Buy Rating for AstraZeneca plc (AZN)
www.americanbankingnews.com - June 5 at 6:06 AM
reuters.com logoAstraZeneca's Lynparza slows advanced breast cancer progression: study
www.reuters.com - June 4 at 10:04 AM

Social

Social activity is not available for this stock.

Chart

AstraZeneca plc (AZN) Chart for Sunday, July, 23, 2017

This page was last updated on 7/23/2017 by MarketBeat.com Staff